When less is more: how many doses of PCV are enough?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial.The Lancet. Infectious diseases · 2023
   Trial
2. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial.The Lancet. Child & adolescent health · 2023
   Trial
3. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.Vaccine · 2024
   Article
4. Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
   Article
5. Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli.Microbial cell factories · 2021
   Article
6. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
   Article
7. Meeting report: Global vaccine and immunization research forum, 2018.Vaccine · 2019
   Article
8. Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage.BMC infectious diseases · 2019
   Article
9. Vaccinology in sub-Saharan Africa.BMJ global health · 2019
   Review
10. Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children.American journal of epidemiology · 2019
    Article

Corrections and comments

• Comment on
  Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as